Anti-IL-4 as a new strategy in allergy

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

22 Scopus citations


Allergic diseases are characterized by an overreaction characterized by Th2-type cell response, and as a consequence, an IgE-switched B cell immunity. Obviously, type-2 cytokines (IL-4, IL-5, IL-9, IL-13) and particularly IL-4 have been identified as potential targets for allergy treatment. While initial experiences using anti-IL-4 principles in asthma were rather ambiguous, more recent studies using an IL-4 mute in blocking the IL-4 and IL-13 receptor have shown promising results. Furthermore, our understanding of IL-4 biology is more specific and may promote more targeted interventions. A key function of IL-4 is the induction of 'master switch' transcription factor GATA3 that drives Th2 differentiation and also effectively inhibits the induction of regulatory T cells. Consequences for treatment of allergic diseases are also discussed.

Original languageEnglish
Title of host publicationNew Trends in Allergy and Atopic Eczema
EditorsJohannes Ring, Heidrun Behrendt, Ulf Darsow
Number of pages6
StatePublished - Mar 2012

Publication series

NameChemical Immunology and Allergy
ISSN (Print)1660-2242
ISSN (Electronic)1662-2898


Dive into the research topics of 'Anti-IL-4 as a new strategy in allergy'. Together they form a unique fingerprint.

Cite this